Navigation Links
Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Date:10/21/2009

mpany's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 26, 2009 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactio
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
2. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
3. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
4. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
5. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
6. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
7. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
8. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
9. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
10. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or ... results of its Oral Amphotericin B (Oral Amp ... study, conducted by ImmuneCarta®, the immune monitoring business ... effectiveness of Oral Amp B in reactivating latent ... despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... Aug. 18, 2014 Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Registration Statement on Form 10 with the U.S. ... Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... , , , , ... Elbit Imaging,(NASDAQ: EMITF ) ("Elbit Imaging" "Company") announced ... - 60%, and Gamida,Cell - 28%; both on a fully diluted ... such subsidiary in a public offering on the,Tel Aviv Stock Exchange ...
... , LIVERPOOL, ... operations of Cambian healthcare Noel Tracey to lead ... Noel has more than 15 years, experience of ... private sector. In his previous role as,director of operations at ...
... DIEGO , Feb. 1 BioMed Realty Trust, Inc. (NYSE: ... fourth quarter and year ended December 31, 2009 after the ... Alan D. Gold , Chairman and Chief Executive Officer, and Kent ... call at 10:00 a.m. Pacific Time on Thursday, February ...
Cached Biology Technology:Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 2Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 3Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 4Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 5Noel Tracey to Head Up Gray Healthcare Recovery Team 2BioMed Realty Trust to Report 2009 Fourth Quarter and Year-End Results 2
(Date:8/19/2014)... abstinence syndrome (NAS) secondary to in-utero opioid exposure ... than others, but the underlying reasons are not ... are turned on or off) changes have recently ... University School of Medicine (BUSM) and Boston Medical ... study to identify some of these epigenetic changes ...
(Date:8/19/2014)... college biology and other science courses are increasingly ... and now they have a new textbook to ... Sciences," published this month by Princeton Press and ... Mathematical and Biological Synthesis (NIMBioS), teaches readers about ... used to explore and explain biological phenomena. , ...
(Date:8/19/2014)... UTSA researchers has been awarded a nearly $40,000 grant ... (NCPTT), an office of the National Park Service (NPS) ... fund a one-year study of the energy efficiency and ... in hot, humid climates. , Radiant barriers are reflective ... reflect heat back, thereby reducing the amount of heat ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... WORCESTER, Mass. Cranberry sauce is not the star ... comes to health benefits, the lowly condiment takes center ... have found that compounds in cranberries are able to ... host of human illnesses (from kidney infections to gastroenteritis ...
... successful wastewater fuel cell, researchers have coaxed common bacteria ... Bruce Logan and colleagues at Penn State University had ... Now, using starter material that could theoretically be sourced ... same microbes to generate hydrogen. By tweaking their ...
... gone" Thats the mystery The Academy of Natural Sciences ... will shed light on the environmental health of the ... less than two inches longonce were abundant in the ... steady decline has prompted Pennsylvania to classify the fish ...
Cached Biology News:Cranberry sauce: good for what ails you 2Cranberry sauce: good for what ails you 3Microbes churn out hydrogen at record rate 2Tiny fish can yield big clues to Delaware River health 2
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
Request Info...
Request Info...
...
Biology Products: